Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Artrya Secures Second US Commercial Order for Salix SaaS Platform to Manage Coronary Artery Disease
Artrya (ASX: AYA) has signed a commercial agreement with US-based Northeast Georgia Health System for the use of its Salix AI cloud platform for point-of-care assessment and management of coronary artery disease.
Latest Stories
Algorae Pharmaceuticals Achieves Independent Validation of AlgoraeOS and Launches Enhanced v2 Platform
Algorae Pharmaceuticals (ASX: 1AI) has reported independent preclinical validation of its AlgoraeOS v1 drug-combination prediction platform following a major study at the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre.
Argenica Study Confirms Compatibility of ARG-007 Candidate with Stroke Treatment Standard-of-Care Therapies
Argenica Therapeutics (ASX: AGN) has reported positive results from a drug-to-drug interaction assessment showing its lead candidate ARG-007 does not interfere with clot-dissolving agent tenecteplase in the treatment of acute ischemic stroke.
Avecho Biotechnology Receives US and EU Patent Allowances for Proprietary CBD Soft-Gel Capsule
Avecho Biotechnology (ASX: AVE) has received patent allowances from both the US Patent and Trademark Office and the European Patent Office for its cannabidiol (CBD) TPM soft-gel capsule.
Optiscan Imaging Launches Head and Neck Cancer Study Using Invue and InForm Digital Pathology Tools
Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch the nation’s first-in-human head and neck cancer imaging study utilising the InVue and InForm digital pathology devices.
Algorae Pharmaceuticals to Partner with Dr Reddy’s for Australian Supply of Chemotherapy Medicine
Algorae Pharmaceuticals (ASX: 1AI) has signed a distribution partnership with Indian multinational Dr Reddy’s Laboratories to supply chemotherapy medicine capecitabine to the Australian market.
Proteomics International Confirms US Reimbursement Price for ProMarkerD Diabetic Kidney Disease Test
Proteomics International Laboratories (ASX: PIQ) has announced that the US Centres for Medicare & Medicaid Services has set a US$390.75 reimbursement price for its PromarkerD predictive test for diabetic kidney disease.
Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26
Aroa Biosurgery (ASX: ARX) has reported total product revenue of NZ$44.9 million for the first six months of financial year 2026, representing growth of 14% on the previous corresponding period.
Argenica Therapeutics Validates Efficacious ARG-007 Dose in New Pre-Clinical Stroke Study
Argenica Therapeutics (ASX: AGN) has released new data from an independent pre-clinical study validating the efficacy and dosing of lead neuroprotective peptide candidate ARG-007 for ischaemic stroke.
Island Pharmaceuticals Joins Medical Countermeasures Coalition to Advance Galidesivir Against High-Priority Virus Threats
Island Pharmaceuticals (ASX: ILA) has been granted membership into the US-based Medical Countermeasures Coalition, an important milestone in its strategy to advance lead candidate galidesivir as a critical countermeasure against high-priority virus threats.
Lumos Diagnostics Secures Full US Medicare Reimbursement Recognition for FebriDx Test
Lumos Diagnostics (ASX: LDX) has achieved complete US Medicare reimbursement recognition for its FebriDx point-of-care diagnostic test, securing coverage from all seven Medicare Administrative Contractors.
Orthocell Reports Accelerated Adoption of Remplir Nerve Repair Technology by Australian Surgeons
Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from peripheral nerve injury.